ABAB Pedia

Daphne Koller

Daphne Koller is an Israeli-born computer scientist and entrepreneur who taught for many years at Stanford UniversityStanford UniversityStanford University is a research university in California founded by Leland and Jane Stanford in 1885 and opened in 1891.Open the full entry and is known for her work on probabilistic graphical models and her 2004 MacArthur Fellowship. She co-founded Coursera with Andrew Ng in 2012 and in 2018 founded insitroinsitroA company applying machine learning to drug discovery and development.Open the full entry, a machine-learning-driven drug discovery company she leads as CEO.

Contents27 sections
Key facts

Born in Jerusalem

Daphne Koller was born on August 27, 1968, in Jerusalem, Israel.⁠[1]

TED’s speaker profile describes her as a third-generation PhD.⁠[2]

Early Degrees at the Hebrew University of Jerusalem

She studied at the Hebrew University of Jerusalem, completing her first degree, a double major in mathematics and computer science, at 17.⁠[3]

She completed her master’s program at the age of 18.⁠[4]

Stanford PhD and Berkeley Postdoc

She earned her PhD at Stanford University in 1993, was a postdoctoral fellow at the University of California, BerkeleyUniversity of California, BerkeleyThe University of California, Berkeley (UC Berkeley) is a campus of the University of California system; the University of California was founded in 1868 through a merger of two institutions and moved to Berkeley, California, in 1873.Open the full entry from 1993 to 1995, joined Stanford’s computer science department as an assistant professor in 1995, and became an associate professor in 2001.⁠[5]

MacArthur Fellowship

In 2004, aged 36, she was named a MacArthur Fellow; the foundation cited her development of “probabilistic relational models” combining logical and statistical representations.⁠[5]

Stanford Partners with Coursera

In March 2012, Stanford announced a partnership with Coursera, the online education start-up she founded with Andrew Ng, to launch five free online courses in mid-March, including her Probabilistic Graphical Models.⁠[6]

TEDGlobal Talk

In June 2012 she gave the TEDGlobal 2012 talk “What we're learning from online education,” describing how Coursera turns every keystroke, quiz and peer-graded assignment into data on how people learn.⁠[7]

Member of the National Academy of Engineering

By September 2014 she was a member of the National Academy of Engineering and a fellow of the American Academy of Arts and Sciences.⁠[4]

Leaves Coursera for Calico

Having served as Coursera’s CEO and later president, she announced in August 2016 that she was leaving to join Calico, a GoogleGoogleGoogle is an American technology company founded by Larry Page and Sergey Brin and incorporated in 1998. It became an Alphabet subsidiary in 2015. Its businesses include internet search, advertising, software platforms, cloud computing, and artificial intelligence.Open the full entry-funded R&D company focused on slowing aging, as chief computing officer, while remaining co-chair of Coursera’s board with Andrew Ng.⁠[8]

At the time Coursera offered more than 1,300 courses to more than 20 million registered users.⁠[8]

Founds insitro

In 2018 she founded the drug discovery company insitro, hoping to create a space where data scientists and molecular biologists could work together as equals.⁠[3]

insitro combines machine learning and genomics, generating much of its own training data with in vitro disease models and automated lab equipment. She said: “We can do experiments in a matter of weeks instead of years.”⁠[9]

Gilead Partnership and Over $100 Million Raised

Appears on the Lex Fridman Podcast

On May 5, 2020, she appeared on episode 93 of the Lex FridmanLex FridmanLex Fridman is a Soviet-born, US-raised computer scientist and podcast host who works as an MIT research scientist on human-AI interaction and autonomous driving. His Lex Fridman Podcast is known for hours-long conversations with guests including heads of state and technology leaders.Open the full entry Podcast, “Biomedicine and Machine Learning”; the outline covers whether all disease could be cured, longevity, her personal journey to medicine, insitro’s “disease-in-a-dish” models, Coursera and education, and AGI and AI safety.⁠[10]

ALS Collaboration with Bristol Myers Squibb

On October 28, 2020, insitro entered a five-year discovery collaboration with Bristol Myers Squibb on amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, receiving $50 million upfront plus $20 million in near-term operational milestones and more than $2 billion in potential milestones and royalties.⁠[11]

$400 Million Series C

On March 15, 2021, insitro announced a $400 million Series C led by CPP Investments. She said: “For insitro, 2020 was a year of incredible growth and progress toward our founding vision.”⁠[12]

Collaboration with Genomics England

On March 9, 2022, insitro and Genomics England announced a collaboration bringing insitro’s machine-learning embedding search to Genomics England’s histopathology images and genetic data, letting users find cases by biologically and clinically relevant similarity.⁠[13]

Named to the TIME100 AI

In September 2024 she was named to the TIME100 AI list. She said: “I've had this increasing sense of urgency to make an actual direct impact in the world.”⁠[14]

Metabolic Disease Agreements with Lilly

On October 9, 2024, insitro signed three metabolic disease agreements with Eli Lilly and Company: insitro may option Lilly’s GalNAc delivery technology for its own siRNA molecules, and the companies will jointly discover an antibody against a third target.⁠[15]

$25 Million in Milestones from Bristol Myers Squibb

On December 18, 2024, insitro said it had received $25 million from Bristol Myers Squibb for discovery milestones and the selection of the first novel ALS target; its platform uses more than 200 engineered and patient-derived ALS cell lines.⁠[16]

Building Models for Lilly TuneLab

On September 9, 2025, insitro announced a collaboration with Lilly to build machine learning models for small molecule drug discovery, offered to biotech companies through Lilly’s new TuneLab platform.⁠[17]

Announces Acquisition of CombinAbleAI

On January 12, 2026, insitro announced it would acquire CombinAbleAI, a biologics AI team in Israel, to form its TherML design platform spanning drug modalities; she noted colleagues in the U.S., Poland and Malaysia.⁠[18]

Brown Adipose Tissue Genetics Study

On February 2, 2026, insitro released a genome-wide association study of brown adipose tissue quantified with computer vision, validating the target BAT-01, whose knockdown cut body weight by 15% in diet-induced obese mice while preserving lean mass.⁠[19]

MASH Candidate Data

On June 8, 2026, at the American Diabetes Association’s 86th Scientific Sessions, insitro presented preclinical data showing its AI-discovered MASH candidate had an anti-fibrotic signal beyond liver-fat reduction; she said its Virtual Human platform used AI-derived liver fat and fibrosis phenotypes to find causal drivers.⁠[20]

Launches Deep Phenotype

On August 26, 2026, insitro launched the Substack publication Deep Phenotype, opening with her essay “Drug Discovery Has No Magic Wands.”⁠[21]

Appoints a Chief Medical Officer Ahead of the Clinic

On September 8, 2026, insitro appointed Hideo Makimura as chief medical officer to lead its transition to a clinical-stage company; she said he had taken more than a dozen programs into the clinic.⁠[22]

Pharmacokinetic Models Go Live in Lilly TuneLab

On October 6, 2026, insitro’s machine learning models for predicting small molecules’ in vivo pharmacokinetics became available in Lilly TuneLab; she said the models make a molecule’s in vivo behavior “a computational question first.” The release said the company was backed by more than $750 million in capital.⁠[23]

On October 15, 2026, insitro entered a worldwide exclusive research collaboration with AstraZeneca on MASH and cardiomyopathies, receiving $40 million upfront and eligible for up to about $1.46 billion in milestones.⁠[24]

As of October 2026: Current Roles

As of October 2026 she is founder and chief executive officer of insitro and an adjunct professor of computer science at Stanford University.⁠[25][26]

The first course of her Probabilistic Graphical Models series on Coursera has more than 95,000 enrolled learners.⁠[27]

Related Organizations, Websites, and Public Accounts

Stanford University: Official website: https://www.stanford.edu/ (opens in a new window)⁠[26]

Sources

  1. Daphne Koller and Andrew Ng (opens in a new window)
  2. Daphne Koller | Speaker | TED (opens in a new window)
  3. BBC Radio 4 - The Life Scientific, Can computers discover new medicines? (opens in a new window)
  4. 10 Machine Learning Experts You Need To Know - Dataconomy (opens in a new window)
  5. Daphne Koller - MacArthur Foundation (opens in a new window)
  6. Stanford partners with Coursera to offer more online courses (opens in a new window)
  7. Daphne Koller: What we're learning from online education | TED Talk (opens in a new window)
  8. Daphne Koller Bids Farewell to Coursera, Hello to Calico (opens in a new window)
  9. Coursera Cofounder Daphne Koller Melds AI And Biology In Drug Startup Insitro (opens in a new window)
  10. #93 - Daphne Koller: Biomedicine and Machine Learning | Lex Fridman Podcast (opens in a new window)
  11. insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (opens in a new window)
  12. insitro Raises $400 Million in Series C Financing (opens in a new window)
  13. insitro and Genomics England Announce Partnership to Provide Multimodal Search Capabilities and Empower Data Exploration and Derivation of Novel Insights - insitro (opens in a new window)
  14. Daphne Koller: The 100 Most Influential People in AI 2024 (opens in a new window)
  15. insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases - insitro (opens in a new window)
  16. insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS - insitro (opens in a new window)
  17. insitro partners with Lilly to build first-in-kind machine learning models to advance small molecule drug discovery - insitro (opens in a new window)
  18. insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design (opens in a new window)
  19. insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects - insitro (opens in a new window)
  20. insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions - insitro (opens in a new window)
  21. Introducing Deep Phenotype: A New Home for Perspectives on AI, Biology, and the Future of Drug Discovery - insitro (opens in a new window)
  22. insitro Appoints Hideo Makimura as Chief Medical Officer to Lead Its Transition to a Clinical-Stage Company - insitro (opens in a new window)
  23. insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab (opens in a new window)
  24. insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies (opens in a new window)
  25. Making Medicines Differently - insitro (opens in a new window)
  26. Daphne Koller's Profile | Stanford Profiles (opens in a new window)
  27. Probabilistic Graphical Models 1: Representation | Coursera (opens in a new window)